| Name | Title | Contact Details |
|---|
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
CFHP was established in 1995, by the University Health System, specifically to begin providing health care coverage to the citizens of Bexar and the surrounding seven counties. As the only locally owned and managed, non-profit health plan in the area,
HMA is a regional third-party healthcare benefits administrator, dedicated to helping the companies we service improve their employee and family health and wellbeing through customized benefits plans and innovative support services.
Art & Drama Therapy Institute is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sarasota Memorial Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Sarasota, FL. To find more information about Sarasota Memorial Hospital, please visit www.smh.com